Clorox (NYSE:CLX – Get Free Report) had its price objective increased by analysts at DA Davidson from $152.00 to $162.00 in a report issued on Friday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. DA Davidson’s price objective suggests a potential upside of 16.40% from the company’s previous close.
Several other equities research analysts have also issued reports on CLX. Jefferies Financial Group assumed coverage on Clorox in a research report on Monday, November 13th. They set an “underperform” rating and a $117.00 target price for the company. UBS Group raised Clorox from a “sell” rating to a “neutral” rating and raised their target price for the company from $124.00 to $132.00 in a research report on Monday, November 6th. StockNews.com assumed coverage on Clorox in a research report on Thursday, October 5th. They set a “hold” rating for the company. Citigroup raised Clorox from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $135.00 to $150.00 in a report on Thursday, November 2nd. Finally, JPMorgan Chase & Co. decreased their price objective on Clorox from $152.00 to $124.00 and set an “underweight” rating for the company in a report on Thursday, October 5th. Six research analysts have rated the stock with a sell rating, eight have issued a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat, Clorox currently has a consensus rating of “Hold” and an average price target of $138.13.
Get Our Latest Analysis on Clorox
Clorox Price Performance
Clorox (NYSE:CLX – Get Free Report) last issued its quarterly earnings data on Wednesday, November 1st. The company reported $0.49 earnings per share for the quarter, beating the consensus estimate of ($0.20) by $0.69. Clorox had a return on equity of 195.76% and a net margin of 1.22%. The business had revenue of $1.39 billion for the quarter, compared to analysts’ expectations of $1.31 billion. During the same period last year, the business earned $0.93 EPS. The business’s revenue was down 20.3% on a year-over-year basis. As a group, analysts forecast that Clorox will post 4.51 EPS for the current fiscal year.
Institutional Trading of Clorox
A number of large investors have recently modified their holdings of CLX. Tyler Stone Wealth Management bought a new stake in shares of Clorox during the 2nd quarter valued at about $25,000. Bogart Wealth LLC boosted its position in shares of Clorox by 105.6% during the 2nd quarter. Bogart Wealth LLC now owns 185 shares of the company’s stock valued at $29,000 after acquiring an additional 95 shares during the last quarter. American National Bank boosted its position in shares of Clorox by 2,466.7% during the 3rd quarter. American National Bank now owns 231 shares of the company’s stock valued at $30,000 after acquiring an additional 222 shares during the last quarter. Ten Capital Wealth Advisors LLC boosted its position in shares of Clorox by 429.7% during the 1st quarter. Ten Capital Wealth Advisors LLC now owns 196 shares of the company’s stock valued at $31,000 after acquiring an additional 159 shares during the last quarter. Finally, Strategic Investment Solutions Inc. IL bought a new stake in shares of Clorox during the 1st quarter valued at about $31,000. Institutional investors own 77.98% of the company’s stock.
Clorox Company Profile
The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.
See Also
- Five stocks we like better than Clorox
- What is Short Interest? How to Use It
- S&P 500’s Whirlwind: Big gains, warning whispers & tactical moves
- How to Start Investing in Penny Stocks
- MarketBeat Week in Review – 11/13 – 11/17
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- 3 large caps with red hot RSIs with upside
Receive News & Ratings for Clorox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox and related companies with MarketBeat.com's FREE daily email newsletter.